Longeveron Inc. has been granted a Chinese patent for potency assay methods used to assess human mesenchymal stem cells (MSCs) from various sources, including bone marrow and umbilical cord. This patent strengthens Longeveron's international portfolio, now totaling 52 patents, supporting its clinical programs and products globally. The company is advancing its laromestrocel (Lomecel-B) therapy, currently in a pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome, with results expected in Q3 2026. The patent protection in China extends through 2041, underscoring Longeveron's strategic focus on stem cell therapies for rare pediatric and aging-related diseases.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
